Automatic Voxel-Based Morphometry of Structural MRI by SPM8 plus Diffeomorphic Anatomic Registration Through Exponentiated Lie Algebra Improves the Diagnosis of Probable Alzheimer Disease

BACKGROUND AND PURPOSE: The necessity for structural MRI is greater than ever to both diagnose AD in its early stage and objectively evaluate its progression. We propose a new VBM-based software program for automatic detection of early specific atrophy in AD.

MATERIALS AND METHODS: A target VOI was determined by group comparison of 30 patients with very mild AD and 40 age-matched healthy controls by using SPM. Then this target VOI was incorporated into a newly developed automated software program independently running on a Windows PC for VBM by using SPM8 plus DARTEL. ROC analysis was performed for discrimination of 116 other patients with AD with very mild stage (n = 45), mild stage (n = 30) and moderate-to-advanced stages (n = 41) from 40 other age-matched healthy controls by using a z score map in the target VOI.

RESULTS: Medial temporal structures involving the entire region of the entorhinal cortex, hippocampus, and amygdala showed significant atrophy in the patients with very mild AD and were determined as a target VOI. When we used the severity score of atrophy in this target VOI, 91.6%, 95.8%, and 98.2% accuracies were obtained in the very mild AD, mild AD, and moderate-to-severe AD groups, respectively. In the very mild AD group, a high specificity of 97.5% with a sensitivity of 86.4% was obtained, and age at onset of AD did not influence this accuracy.

CONCLUSIONS: This software program with application of SPM8 plus DARTEL to VBM provides a high performance for AD diagnosis by using MRI.

ABBREVIATIONS: AD = Alzheimer disease; DARTEL = diffeomorphic anatomic registration through exponentiated lie algebra; FWHM = full width at half maximum; MCI = mild cognitive impairment; MMSE = Mini-Mental State Examination; ROC = receiver operating characteristic analysis; SPM = statistical parametric mapping; VBM = voxel-based morphometry
At the initial visit, they had no apparent loss in general cognitive, behavioral, or functional status and corresponded to the criteria of the amnestic type of MCI or 0.5 in the Clinical Dementia Rating. The MMSE score ranged from 24 to 29 (mean, 25.7 ± 1.5). During the subsequent follow-up period of 2–6 years, the subjects showed progressive cognitive decline and eventually fulfilled the diagnosis of probable AD. The mild and moderate-to-advanced AD groups comprised 30 patients (8 men and 22 women, 71.4 ± 6.8 years of age) and 41 patients (20 men and 21 women, 71.3 ± 7.7 years of age), respectively. The MMSE score ranged from 20 to 25 (mean, 21.4 ± 1.3) and from 6 to 19; (mean, 15.0 ± 3.5) for the mild and moderate-to-advanced AD groups, respectively. Eighty-one of these patients with AD (48 very mild, 11 mild, and 22 moderate-to-advanced) underwent follow-up MRI studies at an interval of 1–4 years for, at most, 6 years (mean, 3.3 ± 1.2 years), and most patients in the very mild and mild AD groups moved to a more advanced group during the follow-up period. Consequently, the total of MRI studies was 89, 37, and 123 for the very mild, mild, and moderate-to-advanced AD groups.

Eighty age-matched control subjects (37 men and 43 women) were healthy volunteers with no memory impairment or cognitive disorders. They ranged in age from 54 to 86 years with a mean of 70.4 ± 7.8 years. Their performance was within normal limits both on the Wechsler Memory Scale—Revised and the Wechsler Adult Intelligence Scale—Revised. Their MMSE scores ranged from 26 to 30 (mean, 29.1 ± 1.2). They did not differ in age or education from the patients with AD. Additionally, 25 healthy volunteers (15 men and 10 women; mean, 31.1 ± 7.8 years of age) participated in this study for creation of a customized template for spatial normalization in the statistical image analysis. The ethics committee approved this study, and all subjects provided informed consent to participate. None of them had asymptomatic cerebral infarction detected by T2-weighted MRI.

All subjects underwent an MRI study on a 1.5T Vision Plus imager (Siemens, Erlangen, Germany). One hundred forty 3D sections of a T1-weighted magnetization-prepared rapid acquisition of gradient echo sequence were obtained in a sagittal orientation as 1.2-mm thick sections (FOV = 23, TR = 9.7 ms, TE = 4 ms, flip angle = 12°, and TI = 300 ms, with no intersection gaps).

First, to define a target VOI for early diagnosis of AD, we performed a group comparison between 30 patients (14 men and 16 women; mean age, 73.8 ± 4.8 years) randomly chosen in the present very mild AD group and the present 40 healthy controls group (19 men and 21 women; mean age, 70.8 ± 8.5 years). Using the latest version of SPM8 (Wellcome Department of Imaging Neuroscience, London, United Kingdom), we segmented MRIs into gray matter, white matter, and CSF images by a unified tissue-segmentation procedure after image-intensity nonuniformity correction. These segmented gray matter images were then spatially normalized to the customized template in the standardized anatomic space by using DARTEL (Wellcome Department of Imaging Neuroscience). The customized template for DARTEL was created from the aforementioned 25 healthy young subjects. To preserve gray matter volume within each voxel, we modulated the images by the Jacobian determinants derived from the spatial normalization by DARTEL and then smoothed them by using an 8-mm FWHM Gaussian kernel. To compare the present analysis by using SPM8 plus DARTEL with the previously reported analysis, we also defined a target VOI by using an old SPM version, SPM2 (Wellcome Department of Imaging Neuroscience) between the same 2 groups. Group comparisons by SPM were assessed by using the family-wise error at a threshold of P < .05, corrected for multiple comparisons.

A stand-alone software program running on Windows for VBM analysis by SPM8 plus DARTEL was developed to discriminate patients with AD from healthy controls. First, MRIs were spatially normalized with only a 12-parameter affine transformation to the SPM template so as to correct for differences in brain size. These linearly transformed images were nonlinearly transformed and then modulated to the customized template for DARTEL, followed by smoothing by using an 8-mm FWHM kernel. Each processed gray matter image of the remaining 116 patients with AD and 40 healthy controls was compared with the mean and SD of gray matter images of the 40 healthy volunteers chosen in the group comparison by using voxel-by-voxel z score analysis with and without voxel normalization to global mean intensities (global normalization): z score = (control mean) − (individual value) / (control SD). These z score maps were displayed by overlay on tomographic sections and surface rendering of the standardized brain. This program registered the target VOI defined by the aforementioned group comparison. This software program takes 8 minutes 40 seconds for all procedures by using a 64-bit PC with a Core i7 central processing unit and 6-gigabytes memory (Intel, Santa Clara, California).

We determined 4 indicators for characterizing atrophy in a target VOI and in the whole brain: first, the severity of atrophy obtained from the averaged positive z score in the target VOI; second, the extent of a region showing significant atrophy in the target VOI—that is, the percentage rate of the coordinates with a z value exceeding the threshold value of 2 in the target VOI; third, the extent of a region showing significant atrophy in the whole brain—that is, the percentage rate of the coordinates with a z value exceeding the threshold value of 2 in the whole brain; and fourth, the ratio of the extent of a region showing significant atrophy in the target VOI to the extent of a region showing significant atrophy in the whole brain. The utility of these indicators for this discrimination of AD from healthy controls has been reported in previous MRI and SPECT studies.

These 4 indicators were obtained under 2 conditions, with or without global normalization. Using the values of the 4 indicators as the threshold, we determined ROC curves for discrimination of patients with AD from healthy volunteers by using JMP 7.0 (SAS Institute, Cary, North Carolina). The program calculates the area under the ROC curves, sensitivity, specificity, and accuracy. Moreover, the age effects of AD onset on these 4 indicators and the results of the ROC were investigated in the very mild AD group classified into 2 subgroups with an age threshold of 65: the early-onset subgroup (16 patients, 9 men and 7 women; mean age, 58.0 ± 4.6 years) and the late-onset subgroup (29 patients, 14 men and 15 women; mean age, 73.8 ± 4.4 years).

**Results**

The group comparison by SPM8 plus DARTEL demonstrated significant decline of gray matter volume in the left (Talairach coordinates −24, −10, −14, x, y, z; z = 7.37 and 6.95 without and with global normalization, respectively) and the right (24, 10, 14, x, y, z; z = 7.42 and 7.05 without and with global normalization, respectively) parahippocampal gyri in patients with very mild AD (Fig 1). These bilateral regions involve the entorhinal cortex, head to tail of the hippocampus, and amygdala and are delineated as a target VOI for AD. Group comparison by SPM2 showed significant decline of gray matter volume in the left (−18, −7, −16, x, y, z; z = 6.18) and right
Fig 1. Group comparison of gray matter volume by SPM8 plus DARTEL and SPM2 between 30 patients with very mild AD and 40 healthy age-matched volunteers. The SPM8 plus DARTEL analysis demonstrates significant decline of gray matter volume in the bilateral medial temporal structures both with and without global normalization in patients with very mild AD. The cluster shape is very close to the anatomic configuration of the medial temporal structures involving the entorhinal cortex, amygdala, and hippocampal formation from head to tail. Although the SPM2 analysis demonstrates a significant decline of gray matter volume in the bilateral medial temporal structures, the cluster is confined to the anterior parts of the medial temporal structures.

Table 1: Values of 4 indicators for characterizing atrophy

<table>
<thead>
<tr>
<th>Group</th>
<th>SPM8 plus DARTEL</th>
<th>SPM2</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Global Normalization</td>
<td>Target VOI</td>
</tr>
<tr>
<td>Healthy controls</td>
<td>–</td>
<td>0.7 ± 0.5</td>
</tr>
<tr>
<td></td>
<td>+</td>
<td>0.7 ± 0.3</td>
</tr>
<tr>
<td>Very mild AD</td>
<td>–</td>
<td>1.8 ± 0.9b</td>
</tr>
<tr>
<td></td>
<td>+</td>
<td>2.2 ± 0.9b</td>
</tr>
<tr>
<td>Mild AD</td>
<td>–</td>
<td>2.2 ± 0.7b</td>
</tr>
<tr>
<td></td>
<td>+</td>
<td>2.7 ± 0.8b</td>
</tr>
<tr>
<td>Moderate-to-advanced AD</td>
<td>–</td>
<td>2.8 ± 1.0b,c,d</td>
</tr>
<tr>
<td></td>
<td>+</td>
<td>3.0 ± 1.0b,c,d</td>
</tr>
</tbody>
</table>

Note: —NA indicates not applicable; +, presence; –, absence.

* Tukey honest significance test in each condition of global normalization.
* P < .001 versus healthy controls.
* P < .001 versus very mild AD group.
* P < .001 versus mild AD group.

The patients with AD showed significantly (P < .001, Tukey honest significance test) greater values than healthy controls in all 4 indicators in both SPM8 plus DARTEL and SPM2 analysis (Table 1). The mild AD group showed not significant but greater values of all 4 indicators than the very mild AD group. The moderate-to-advanced AD group showed significantly (P < .001) greater values of severity and extent for the target VOI and extent for the whole brain than the very mild AD group. In contrast, the ratio for the target VOI in the moderate-to-advanced AD group was lower than that in the mild AD group and almost equal to that in the very mild AD group. Global normalization in SPM8 plus DARTEL analysis elevated the severity and ratio for the target VOI and diminished the extent for the whole brain in all AD groups. The SPM2 analysis showed lower values in severity, extent, and ratio for a target VOI and greater values in extent for the whole brain than the SPM8 plus DARTEL analysis.

In the SPM8 plus DARTEL analysis, better ROC results were obtained in the condition with than without global normalization, particularly in specificity (On-line Table 1). Of the

(18, –5,15, x,y,z; z = 5.86) parahippocampal gyri (Fig 1). The cluster size was smaller in SPM2 than in SPM8 plus DARTEL.
4 indicators, the severity and extent for the target VOI with global normalization showed almost equal and high accuracy. Even in the very mild AD group, the severity showed a high accuracy of 91.6%, increasing to 95.8% in the mild AD group and 98.2% in the moderate-to-advanced AD group. SPM8 plus DARTEL showed better ROC results for all 4 indicators than SPM2.

Although the early-onset subgroup showed lower values of indicators for the target VOI than the late-onset subgroup (Table 2), global normalization elevated these indicators evenly in the early- and late-onset subgroups. These indicators were largely stable before and after global normalization in healthy controls. Consequently, ROC results in SPM8 plus DARTEL revealed equal accuracy after global normalization between these 2 subgroups (Online Table 2). In contrast, SPM2 analysis showed approximately 10% lower accuracy in the early-onset subgroup than that in the late-onset subgroup when using the severity score.

In each of 81 follow-up patients with AD, the severity score in a target VOI gradually increased from the baseline to follow-up studies. The annual increase of the severity score after global normalization was 0.27 ± 0.15.

Representative cross-sectional and longitudinal studies for SPM8 plus DARTEL analysis are demonstrated in Figs 2 and 3, respectively.

**Discussion**

Using severity as an indicator, we obtained a high sensitivity of 86.4% and extremely high specificity of 97.5%, resulting in an accuracy of 91.6% for discrimination of patients with very mild AD from healthy controls in the SPM8 plus DARTEL analysis. Extremely high specificity mainly contributed to this high accuracy. In the SPM2 analysis, ROC analysis presented 5% lower sensitivity and approximately 13% lower specificity compared with those in the SPM8 plus DARTEL analysis. Kawachi et al\(^\text{12}\) reported 82.9% in both sensitivity and specificity in the patients with very mild AD in a similar VBM study by using an older SPM version, SPM99. This better specificity may result from application of the SPM8 plus DARTEL algorithm. This DARTEL algorithm can provide more precise spatial normalization to the template than the conventional algorithm.\(^\text{10,13}\)

This improvement in the preciseness of the spatial normalization was confirmed by group comparison for determining a target VOI. The SPM8 plus DARTEL results showed significantly decreased volume with anatomically precise configura-

### Table 2: Values of 4 indicators in early- and late-onset subgroups in very mild AD

<table>
<thead>
<tr>
<th>Global Normalization</th>
<th>Onset</th>
<th>Target VOI</th>
<th>Whole-Brain Extent (%)</th>
<th>SPM8 plus DARTEL</th>
<th>SPM2</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td>Severity</td>
<td>Extent (%)</td>
<td>Ratio</td>
<td></td>
</tr>
<tr>
<td>− Early</td>
<td>1.5 ± 0.7</td>
<td>25.3 ± 31.1</td>
<td>3.8 ± 3.8</td>
<td>5.1 ± 4.9</td>
<td>5.1 ± 4.9</td>
</tr>
<tr>
<td>− Late</td>
<td>1.9 ± 0.9</td>
<td>43.8 ± 35.6</td>
<td>5.9 ± 8.4</td>
<td>11.6 ± 9.5</td>
<td>11.6 ± 9.5</td>
</tr>
<tr>
<td>+ Early</td>
<td>1.9 ± 0.7</td>
<td>37.4 ± 26.2</td>
<td>9.5 ± 6.0</td>
<td>4.1 ± 1.7</td>
<td>4.1 ± 1.7</td>
</tr>
<tr>
<td>+ Late</td>
<td>2.3 ± 0.9</td>
<td>53.6 ± 30.7</td>
<td>14.1 ± 8.1</td>
<td>4.1 ± 2.7</td>
<td>4.1 ± 2.7</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Target VOI</td>
<td>Whole-Brain Extent (%)</td>
<td>SPM8 plus DARTEL</td>
<td>SPM2</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Severity</td>
<td>Extent (%)</td>
<td>Ratio</td>
<td></td>
</tr>
<tr>
<td>− Early</td>
<td>NA</td>
<td>NA</td>
<td>NA</td>
<td>NA</td>
<td>1.4 ± 1.0</td>
</tr>
<tr>
<td>− Late</td>
<td>NA</td>
<td>NA</td>
<td>NA</td>
<td>NA</td>
<td>1.7 ± 1.0</td>
</tr>
<tr>
<td>+ Early</td>
<td>1.4 ± 1.0</td>
<td>24.4 ± 34.6</td>
<td>4.7 ± 5.5</td>
<td>3.8 ± 2.4</td>
<td>3.8 ± 2.4</td>
</tr>
<tr>
<td>+ Late</td>
<td>1.7 ± 1.0</td>
<td>33.2 ± 31.2</td>
<td>7.5 ± 8.5</td>
<td>6.0 ± 3.9</td>
<td>6.0 ± 3.9</td>
</tr>
</tbody>
</table>

Note: —NA indicates not applicable; +, presence; −, absence.
tion of the medial temporal structures involving the entorhi-
nal cortex, amygdala, and total hippocampal formation. Takahashi et al demonstrated almost identical results by us-
ing SPM8 plus DARTEL. The present SPM results by using conventional VBM by SPM2 showed decreased gray matter volume mainly in the anterior parts of the parahippocampal gyri with a less precise configuration. The severity score proved to be useful for longitudinal studies as well. The annual increase of this score may be indicative of disease progression. The modulation in VBM allows comparison of the absolute amount of gray matter. The step of global normalization allows correction of the absolute amount of gray matter for individual total brain volume. Comparison of discrimination performance demonstrated better results in the condition with than without global normalization. This difference in discrimination performance may arise from the well-known fact of selective atrophy in the medial temporal structures in AD. Even if the absolute amount of gray matter of the medial temporal structures is decreased, a concomitant decrease in the total volume of gray matter would decrease specificity. The specificity in ROC analysis of the severity for the target VOI was 17% lower in the condition without than with global normalization in very mild AD. The degree of selective atrophy in the medial temporal areas can be assessed by the ratio as an indicator. In patients with AD, more than 10-fold selective atrophy was observed in the medial temporal areas compared with the whole brain in SPM8 plus DARTEL. Global normalization enhanced this ratio. Progression of neocortical atrophy would result in the decline of this ratio in advanced AD. This indicator may be useful for differentiation of AD from other neuropsychiatric diseases manifesting dementia.

The early-onset subgroup showed milder atrophy in the medial temporal structures than the late-onset subgroup. This is in line with several previous reports in which late-onset subgroups showed greater atrophy in the medial temporal structures than the early-onset subgroups. However global normalization in SPM8 plus DARTEL extended the difference of indicators for a target VOI evenly in the early-onset and late-onset subgroups from indicators in healthy controls. This extension led to almost equal accuracy for discrimination of early-onset and late-onset very mild AD from healthy controls. This global normalization procedure may make it possible to use a common target VOI irrespective of age at onset of AD.

Thus the present study made it clear that the global normalization procedure in VBM by using SPM8 plus DARTEL has advantages in enhancing the discrimination power of diagnosing AD. However lower values of the extent for the whole brain after global normalization would underestimate neocor-

Fig 3. Longitudinal VBM studies by using SPM8 plus DARTEL. A 63-year-old woman with an MMSE score of 27 at the first visit was followed up for 6 years. One year later, the MMSE score decreased to 20 and gradually decreased thereafter. VBM analysis with global normalization reveals significant atrophy in the bilateral medial temporal areas even at the time of the initial study. Then the z score in a target VOI increased step by step with time. In contrast, analysis without global normalization does not demonstrate significant atrophy in the medial temporal areas for the first 3 years. Severity scores as an indicator for characterizing atrophy in the medial temporal structures are shown.
tical atrophy. The extent for the whole brain without global normalization may be useful for accurately evaluating the degree of neocortical atrophy.

This study is not without limitations. First, we should investigate whether this 1-site study is applicable to multicenter studies. Second, evaluation of the reproducibility of the present VBM technique may be necessary for longitudinal studies. Third, we investigated patients with amnestic MCI who all converted to AD. The outcome for any patient with MCI is uncertain because many subjects remain stable or even revert to a normal state, while others progress to dementia. Accordingly, the predictive study by using this VBM approach is much more important for MCI conversion to AD. Fourth, the single target VOI was used irrespective of age at onset of AD. A similar VBM study by Ishii et al. recommended the use of a target VOI involving not only medial temporal structures but also parietal and posterior cingulate cortices and precunei in early-onset AD. Although this software program presented the same accuracy between early- and late-onset very mild AD subgroups, we may have to investigate a more appropriate target VOI from a larger number of patients with early-onset AD. However, incorporation of 2 types of target VOIs for early- and late-onset AD into a software program may confound the program user in the selection of a target VOI in the case of follow-up studies on an approximately 65-year-old patient.

Conclusions
We proposed an automatic VBM software program of structural MRI for discrimination between patients with probable AD from the very-mild- to advanced stages and age-matched healthy controls. Application of the SPM8 plus DARTEL analysis to this software program provided a high accuracy of 91.6% for discrimination of patients with very mild AD from healthy controls by using a target VOI located in medial temporal structures. Equal accuracies were obtained in early-onset and late-onset very mild AD subgroups. This software program may be useful for early diagnosis and longitudinal evaluation of AD.

References